Catalent, Inc. (NYSE:CTLT) Shares Bought by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. lifted its holdings in Catalent, Inc. (NYSE:CTLT) by 2.6% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 9,133 shares of the company’s stock after acquiring an additional 229 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Catalent were worth $553,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Catalent in the second quarter worth approximately $42,000. Sentry Investment Management LLC purchased a new position in shares of Catalent in the third quarter worth approximately $53,000. Longfellow Investment Management Co. LLC increased its position in shares of Catalent by 45.7% in the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after acquiring an additional 305 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Catalent by 25.9% in the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after acquiring an additional 212 shares in the last quarter. Finally, Intact Investment Management Inc. purchased a new position in shares of Catalent in the third quarter worth approximately $73,000.

Insider Buying and Selling at Catalent

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the sale, the director now directly owns 10,835 shares in the company, valued at $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the transaction, the insider now directly owns 36,304 shares in the company, valued at approximately $2,177,150.88. This represents a 5.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,114 shares of company stock worth $305,931 over the last ninety days. 0.31% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

CTLT has been the topic of several analyst reports. StockNews.com raised shares of Catalent from a “sell” rating to a “hold” rating in a research report on Thursday. Baird R W downgraded shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Robert W. Baird restated a “neutral” rating and set a $63.50 price target on shares of Catalent in a report on Tuesday, September 24th. Finally, William Blair restated a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Eight investment analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $63.40.

Catalent Stock Performance

CTLT stock opened at $59.10 on Friday. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. The stock has a market cap of $10.73 billion, a P/E ratio of -26.15, a P/E/G ratio of 2.35 and a beta of 1.16. The firm has a 50 day simple moving average of $59.84 and a 200 day simple moving average of $58.20. Catalent, Inc. has a 52 week low of $36.74 and a 52 week high of $61.20.

Catalent (NYSE:CTLT) last posted its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. Catalent’s revenue was up 4.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.10) earnings per share. Research analysts anticipate that Catalent, Inc. will post 0.84 earnings per share for the current fiscal year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.